| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -110,555 | -92,648 |
| Depreciation and amortization | 385 | 242 |
| Net amortization of debt premium and discount (related party of 182 and 99) | 182 | 92 |
| Loss on impairment of goodwill | 0 | 0 |
| Loss on financial instruments, net (related party of and (538)) | 166 | -45 |
| Investment income (loss), net | -15,938 | -12,776 |
| Non cash interest expense (related party of 5,573 and 4,622) | 7,364 | 2,764 |
| Non cash interest income | 256 | 139 |
| Non cash share-based compensation | 923 | 461 |
| Provision for credit losses | 0 | 0 |
| Accrual (release) of loss contingency related to arbitration award | 62,831 | 62,831 |
| Provision for deferred taxes | 43 | - |
| (gain) loss on liability resolution | 0 | - |
| Changes in other assets | 955 | -1,101 |
| Changes in accounts payable and accrued expenses | -1,098 | 1,639 |
| Changes in other liabilities and deferred revenue | 0 | 0 |
| Net cash used in operating activities | -25,364 | -10,836 |
| Return of investments in alternative assets held by customer exalt trusts | 7,780 | 3,711 |
| Proceeds from disposition of alternative assets held by customer exalt trusts | 37,174 | 24,059 |
| Purchase of investments in alternative assets held by customer exalt trusts | 2,033 | 1,219 |
| Purchase of premises and equipment | 96 | 96 |
| Net cash provided by investing activities | 42,825 | 26,455 |
| Proceeds from related party debt financings | 850 | 850 |
| Payments on related party debt financings | 15,026 | 10,474 |
| Proceeds from issuance of convertible debt | 0 | - |
| Proceeds received from issuance of class a common shares under equity purchase agreement | 271 | 271 |
| Payment of deferred financing costs for equity | 0 | 0 |
| Proceeds from sale of class a common shares | 0 | - |
| Net cash (used in) provided by financing activities | -13,905 | -9,353 |
| Net increase (decrease) in cash and cash equivalents | 3,556 | 6,266 |
| Cash and cash equivalents at beginning of period | 1,346 | 1,346 |
| Cash and cash equivalents at end of period | 4,902 | 7,612 |
Beneficient (BENF)
Beneficient (BENF)